Drug Discovery World

AUGUST 30, 2022

The Phacilitate Advanced Therapies Europe 2022 conference will take place from 30 August to 1 September at the Royal Lancaster in London, UK. The conference is the European twin to Phacilitate Advanced Therapies Week, an event held in January in Florida, US. Improving patient experience within clinical trials and long term follow up.

Therapies 246

Therapies Hospitals Clinical Trials Clinical Development 246

Drug Discovery World

MARCH 25, 2024

Cardior is focused on the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart. We have been impressed by the scientific work carried out by the Cardior team, especially on CDR132L, which has a distinctive mode of action and potential to become a first-in-class therapy.”

Therapies 130

Therapies RNA Disease Trials 130

PPD

SEPTEMBER 16, 2024

ML is also used to identify predictors of response to a therapy or risk for adverse events (AEs) that can be used to inform value-based contracting or treatment strategies intended to minimize “wasted” use of a drug. Ready to learn more about convergence of real-world data and technology for clinical trials?

52

52

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? The deeper the understanding of product and process from a characterisation standpoint, the smoother the regulatory conversations and development pathway will be.”

Therapies 130

Therapies Clinical Trials Marketing Production 130

Drug Discovery World

OCTOBER 3, 2023

The agency is inviting a limited number of sponsors to participate in the programme, which allows for more frequent communication with FDA staff to address clinical development issues. “We The post FDA pilot programme to boost rare disease therapies appeared first on Drug Discovery World (DDW).

FDA 130

FDA Disease Therapies Clinical Trials 130

Drug Discovery World

DECEMBER 20, 2022

The first gene therapy for haemophilia B could soon be available to patients in Europe following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP). . The therapy was also recently approved by the FDA for patients in the US. .

Therapies 130

Therapies Clinical Trials Licensing Licensing 130

Drug Discovery World

SEPTEMBER 6, 2022

In recent years the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are not only transforming the way diseases are treated but are also aiming to cure entirely new patient populations. Record breaking investments in 2021 fuel an industry on fire . billion raised.

Therapies 130

Therapies Clinical Trials Production Disease 130

Drug Discovery World

JULY 12, 2024

Following the success of therapies like Ozempic, it’s no surprise that type 2 diabetes research is being prioritised by biopharmaceutical companies. High levels of cancellations at Phase II not only increase the costs of clinical development, but also have a knock-on effect on the rate at which new therapies reach patients.

Research 147

Research Clinical Trials Clinical Development Trials 147

Drug Discovery World

JULY 11, 2022

David Lewandowski, Business Director of Cell & Gene Therapy at Azenta Life Sciences, explains how efficient sample management can help to work efficiently and bring therapies to market faster. It has been estimated that by 2025 the FDA will be approving 10 to 20 cell and gene therapy products per year 2.

Therapies 130

Therapies Clinical Trials Production Trials 130

Drug Discovery World

JANUARY 11, 2024

They are called: mRNA technology may hold the future for a cytomegalovirus vaccine ; Predictive diagnostics: closing the precision medicine gap ; and FAIR Game: making data work harder in the race to market. In the first article, Allison August, M.D.,

Vaccine 147

Vaccine Clinical Development Drugs Marketing 147

Drug Discovery World

JANUARY 23, 2024

What has been especially notable is the increase in solid tumour trials – these are likely to be the foundation of innovative cancer therapies, and investment in this area is a promising sign for patients,” explained Dr Gen Li, President, Phesi. Read the full report.

Disease 130

Disease Clinical Trials Research Trials 130

Drug Discovery World

JANUARY 11, 2024

They are called: mRNA technology may hold the future for a cytomegalovirus vaccine ; Predictive diagnostics: closing the precision medicine gap ; and FAIR Game: making data work harder in the race to market. In the first article, Allison August, M.D.,

Vaccine 130

Vaccine Drugs Clinical Development Marketing 130

Drug Discovery World

FEBRUARY 12, 2024

“In the upcoming year, we will see the expansion of new, more complex markets and updated requirements from regulators. Without fixing the current, broken PV models, the continuous cycle of more complexity in the market, which then pushes organisations to incorporate automation into insufficient processes, will massively hinder PV operations.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Drug Discovery World

JULY 17, 2023

Analysis of 13,490 clinical trials finds almost a third have been cancelled during Phase II amidst an overall decline in clinical development productivity. Data analytics company Phesi has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date.

Clinical Trials 130

Clinical Trials Trials Clinical Development Therapies 130

Drug Discovery World

FEBRUARY 10, 2023

Three of the top five most-studied disease areas fell within oncology, with prostate cancer the third most-studied disease, solid tumours fourth, and stroke fifth. “Oncology remains an area of high investment in clinical development, however, 2022 has seen a widespread scale back of overall activity.

Disease 130

Disease Clinical Trials Clinical Development Trials 130

The Pharma Data

OCTOBER 21, 2020

and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme. Of those participants who transitioned back to injectables, the median duration of oral therapy was 51 days.

Clinical Development 52

Clinical Development Therapies Clinical Trials FDA Approval 52

Drug Discovery World

JANUARY 25, 2024

Orphan Drug Designation qualifies companies for incentives, including tax credits for clinical trials, exemption of user fees, and seven years of market exclusivity after approval. Our team is dedicated to advancing this therapy through clinical development as swiftly as possible.”

FDA 130

FDA Drugs Clinical Trials Clinical Development 130

Drug Discovery World

NOVEMBER 21, 2023

Fosun Pharma USA and Treehill Partners have formed a jointly operating vehicle for investment in clinical stage assets. The new business will be looking for high-quality, mid- to late-stage assets, clinically focused on the US market.

Clinical Development 130

Clinical Development Production Marketing Drug Development 130

Drug Discovery World

SEPTEMBER 14, 2023

Patients with mUC, including FGFR-driven tumours, face a particularly poor prognosis and the need for innovative therapies remains high. Patients with mUC, including FGFR-driven tumours, face a particularly poor prognosis and the need for innovative therapies remains high.

Treatment 130

Treatment Clinical Pharmacology FDA Approval Therapies 130

Drug Discovery World

APRIL 14, 2023

Dr Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated, safe and developable bi-specific therapeutic ADC candidates to clinical development. This is even more relevant for combination therapies or bispecific antibodies.

Drug Development 130

Drug Development Drugs Clinical Trials Therapies 130

The Pharma Data

NOVEMBER 29, 2020

Prior to joining Gannex, Dr. Palmer was Head of Liver Disease Clinical Development at Takeda Pharmaceuticals. She has also held senior leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of NASH and other liver disease programs. . ” About Ascletis.

Clinical Development 40

Clinical Development Disease Clinical Trials Pharmaceutical Companies 40

Conversations in Drug Development Trends

DECEMBER 7, 2023

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture. We are acutely aware that turnover in key project team personnel can lengthen project timelines and inflate clinical trial costs.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

Drug Discovery World

DECEMBER 7, 2022

If clinical research into collagen maintains this momentum, we can expect to see innovations in wound healing and bone care making their way to patients in the coming years.”. In 2021, the global collagen market was valued at $9.75 However, the industry has been slow to invest in collagen-related clinical research.

Clinical Trials 130

Clinical Trials Trials Clinical Research Clinical Development 130

Drug Discovery World

MAY 6, 2024

During the period 2016-2021, the Brazilian, Chinese and Indian markets grew by 11.7%, 6.7% respectively compared to an average market growth of 5.8% for the top five European Union markets and 5.6% for the US market 2. However, Europe is facing increasing competition from emerging economies.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics.

Therapies 40

Therapies RNA Licensing Licensing 40

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding. Northern Ireland “Northern Ireland is a medtech super-hub,” says Saleko.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

JUNE 29, 2023

David Favre, Chief Development Officer, SpliceBio Dr Favre brings more than 25 years of experience in gene therapy, immunology and drug development throughout academia and the biopharma industry. Hasan Hallaq, European Sales Director, Victoria Ordsmith, Director of Marketing, and Sarennah Longworth-Cook, Director of People, H.E.L

Drugs 130

Drugs Laboratories Research Laboratories Clinical Trials 130

The Pharma Data

SEPTEMBER 29, 2021

Patients are going to be randomized to receive either finerenone 10mg or 20mg or placebo on top of individually tolerated maximum labeled doses of a renin-angiotensin system (RAS)-blocking therapy like an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB).

Clinical Development 52

Clinical Development Disease Clinical Trials Trials 52

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

Drug Discovery World

FEBRUARY 10, 2023

The top stories: Study shines a light on representation in clinical research A diversity study has shown that clinical trials should use real world diseases epidemiology data, rather than US Census Bureau race and ethnicity data, to ensure enrolment reflects the populations affected by different diseases.

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

Drug Discovery World

MARCH 24, 2023

Additionally, the trial design incorporates feedback from Scientific Advice meetings with the European Medicines Agency (EMA) to support a Marketing Authorisation Application (MAA). The Phase III will have overall survival as the primary objective and may include a specific patient population.

Trials 130

Trials Immune Response FDA Clinical Development 130

Drug Discovery World

JUNE 16, 2023

Globally, the aggregate annual market potential of LP-184/STAR-001’s programs is estimated to be approximately $11-13 billion, consisting of $6-7 billion for solid tumours and $5-6 billion for CNS cancers.

FDA 130

FDA Clinical Trials Drugs DNA 130

Drug Discovery World

JULY 2, 2024

OECD data places Switzerland second in the world for biotechnology R&D intensity 1 , and in 2021, the country had the seventh largest share of the global biotech market 2. In 2005, Glycart was acquired by the Roche Group and integrated in Roche Pharma Research and Early Development (pRED). So what makes it so successful?

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Discovery World

OCTOBER 4, 2022

Erhardt adds that despite the ever-increasing number of people with AD, there has been an erosion of market value (from $4.2 Oligomerix believes it is focused on the most important segment of the neuroscience market which is the Alzheimer’s/dementia space. is President, Head of Development & Operations of Oligomerix.

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

PPD

MARCH 26, 2024

A large majority of drug developers utilize FSP or hybrid FSP/FSO models, half are “heavy users” Heavy users: Those that use FSP or hybrid FSP/FSO models for most of their clinical development outsourcing. Heavy users leverage these models for nearly three-quarters of their outsourcing.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Research Clinical Development Drug Development 98

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim is pioneering a range of versatile therapeutic platforms in order to develop innovative medicines that target the tumor directly (tumor cell-directed therapies) or that enable the immune system to target the tumor (immune cell-targeted therapies). About Boehringer Ingelheim.

Licensing 52

Licensing Licensing Therapies Science 52

Vial

APRIL 24, 2024

In addition to the areas above (aside from DTx), Syneos Health offers biosimilars , cell and gene therapy , endocrine and metabolic, immunology and inflammation, infectious diseases, pediatrics, respiratory, and women’s health services. Digital therapeutics is not explicitly listed as a therapeutic area of expertise for Syneos Health.

Clinical Trials 52

Clinical Trials Biosimilars Trials Disease 52